Global Patent Index - EP 0434727 A4

EP 0434727 A4 19940817 - RED-SHIFTED PHTHALOCYANINE AND TETRABENZTRIAZAPORPHYRIN REAGENTS

Title (en)

RED-SHIFTED PHTHALOCYANINE AND TETRABENZTRIAZAPORPHYRIN REAGENTS

Publication

EP 0434727 A4 19940817 (EN)

Application

EP 89910330 A 19890831

Priority

  • US 24160888 A 19880908
  • US 39843389 A 19890829

Abstract (en)

[origin: WO9002747A1] Red-shifted, water-soluble, fluorescent, monomerically-tetherable derivatives having formula (I), wherein M represents either H2 or is selected from among the following metals: aluminum, silicon, phosphorus, gallium, germanium, cadmium, scandium, magnesium, tin, and zinc. Each R1 is independently selected from -XYW, -YW, and -W. X represents either a carbon, or heteroatom selected from among oxygen, nitrogen, sulfur, phosphorus, silicon, and selenium; Y represents a linking group; and W represents a water solubilizing group. The substituent R2 is selected from among -A, -Y'A, -XA, and -XY'A, where A denotes a biological entity such as an antibody, antibody fragment, nucleotide, nucleic acid probe, antigen, oligonucleotide, deoxynucleotide, dideoxynucleotide, avidin, streptavidin or membrane probe, or R2 is a reactive or activatable group suitable for conjugating to a biological entity. Y' is a linking group that tethers the biological entity to the phthalocyanine or tetrabenztriazaporphyrin macrocycle. Z is either a nitrogen atom or a carbon substituted with hydrogen, alkyl, aryl, or aralkyl groups. Z may also be attached to R2. Also disclosed are derivatives of the compounds of formula (I) in which 1-4 of the benzo ring(s) contain 1 or 2 N atoms. Methods of sequencing DNA and detecting analytes, including cells, using these derivatives are disclosed, as are kits for carrying out assays for the analytes and flow cytometry. Methods of detecting DNA using cationic compounds of formula (I), wherein R2 = R1 and W = -N<+>D1D2D3 are also disclosed. Further, compounds containing Tc, Gd, etc. as the metal in formula (I) may be used for imaging or therapy.

IPC 1-7

C07D 487/22

IPC 8 full level

A61K 31/40 (2006.01); A61K 41/00 (2006.01); A61P 35/00 (2006.01); C07D 487/22 (2006.01); C07H 21/00 (2006.01); C07H 21/04 (2006.01); C07K 14/00 (2006.01); C07K 14/705 (2006.01); C07K 16/00 (2006.01); C09B 47/00 (2006.01); C12Q 1/68 (2006.01); G01N 33/533 (2006.01)

CPC (source: EP)

A61K 41/0071 (2013.01); A61P 35/00 (2017.12); C07H 21/00 (2013.01); G01N 33/533 (2013.01); C12Q 1/6869 (2013.01)

Citation (search report)

  • No further relevant documents disclosed
  • See references of WO 9002747A1

Designated contracting state (EPC)

AT BE CH DE FR GB IT LI LU NL SE

DOCDB simple family (publication)

WO 9002747 A1 19900322; AU 4216389 A 19900402; AU 642396 B2 19931021; CA 1337754 C 19951219; EP 0434727 A1 19910703; EP 0434727 A4 19940817; JP H04500516 A 19920130

DOCDB simple family (application)

US 8903807 W 19890831; AU 4216389 A 19890831; CA 610514 A 19890907; EP 89910330 A 19890831; JP 50958389 A 19890831